Department of Research Infrastructure Division of Biobank
List of our Programs
- Program for Promoting Platform of Genomics based Drug Discovery
- BioBank Japan Project for Genomic and Clinical Research
- Program for an Integrated Database of Clinical and Genomic Information
- Platform Program for Promotion of Genome Medicine
- National BioResource Project (NBRP)
- Tohoku Medical Megabank Project
- Public Understanding and Information Sharing on Research Ethics (Ethical, legal and social issues on the practical application of genome medicine)
- Tailor-Made Medical Treatment with the BioBank Japan Project (BBJ)
List of our News
2019.8.5Integrative genome analysis identified the KANNO blood group antigen as prion protein
2019.7.23Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease
2019.7.17Germline pathogenic variants in 7,636 Japanese patients with prostate cancer and 12,366 controls
2019.7.9Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression
2019.6.13Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling
2019.3.26GWAS of smoking behaviour in 165,436 Japanese people reveals seven new loci and shared genetic architecture
2019.2.5Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population
2019.2.4AMED’s “GEM Japan” Project Joins GA4GH Driver Projects
2019.1.29Genetic and phenotypic landscape of the MHC region in the Japanese population
2018.12.26International survey on medical R&D strategy planning method based on public health information
Profile of the Division of Biobank
In light of the rapid progress in analysis technology at the genomic level, the Division of Biobank strives to strengthen the foundation of genome analysis while encouraging R&D to clarify how genetic and environmental factors relate to specific diseases and promote clinical applications of the findings with the aim of swiftly returning to the public the benefits of the clarification.
Specifically, while working to establish a biobank for specimens of diseases and healthy donors, the department analyzes such data as genome analysis information and clinical information to identify and verify the genes related to the onset of diseases and drug responsiveness and to identify the standard genome sequence of Japanese people. In addition, through collaborative and ancillary genome research, the department not only aims to track down the causal genes of rare/intractable diseases, but also to contribute to the formulation of innovative diagnostic/treatment guidelines based on genome information. Furthermore, the department is pushing forward experimental/empirical clinical research to strengthen the research foundation and establish a system for offering genomic medical care toward the goal of turning genomic medicine into reality.
Through these initiatives, the department aims to achieve the following by 2020.
- To find evidence associated with risk prediction/prevention, diagnosis (stratification), treatment, and drug selection/optimization for diabetes and other diseases
- To commence clinical research associated with predictive cancer diagnostics and treatment responses to anticancer and other drugs, and prediction of their side effects
- To commence clinical research associated with genomic medicine in the fields of dementia and sensory systems
- To commence clinical research associated with innovative methods of diagnosis and treatment for intractable neuromuscular diseases
Under AMED's Japan Genomic Medicine Project, the Data-sharing Policy for the Realization of Genomic Medicine was formulated to clarify the policy to be followed with respect to the sharing of genome information with the aim of promoting data sharing in related fields.
Furthermore, under the National BioResource Project, bioresources such as experimental animals, plants and micro-organisms that are of fundamental importance in life science research and critical for the nation to strategically organize are systematically collected, preserved and provided. In addition, with the aim of enhancing the quality of bioresources, efforts are made to secure bioresources that meet the needs of the time by developing preservation technologies and adding more value to them by way of genome analysis.
Data sharing Policy for the Realization of Genomic Medicine
Under the Japan Genomic Medicine Project, which is one of AMED's nine interrelated areas, the Data sharing Policy for the Realization of Genomic Medicine was formulated, making data sharing obligatory as a general rule. With the objective of practicing prompt, extensive and appropriate disclosure and sharing of genome data associated with research outcomes and genome information including clinical information and analysis/interpretation results, the Policy defines a framework for protecting the rights of research participants and researchers who provided the data and information, while, at the same time, facilitating research in related fields through data sharing.
The GEM Japan (GEnome Medicine Alliance Japan), whose purpose is to integrate the results of AMED projects toward the realization of genomic medicine in Japan, was designated as a GA4GH Driver Project.
- About GEM Japan